Blinatumomab
Summary
Hazard - P - B - T - Risk Exempt
Assessment report
Assessment report for BLINCYTO (blinatumomab), 24 September 2015, EMA/CHMP/469312/2015.
"Blinatumomab is a protein, the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, blinatumomab it is not expected to result in a significant risk to the environment."
Fass environmental information
Fass environmental information for BLINCYTO from Amgen (downloaded 2019-09-04).
Risk
The use of amino acids, proteins and peptides is not expected to have any environmental impact.
Detailed information
According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
References
- European Medicines Agency. European public assessment reports (EPAR). BLINCYTO (blinatumomab), 24 September 2015, EMA/CHMP/469312/2015.
- Fass för vårdpersonal.
- European Medicines Agency, EMA: Committee for Medicinal Products for Human Use (CHMP). Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. 1 June 2006.
Author: Health and Medical Care Administration, Region Stockholm